💉 Retatrutide: The Triple Threat That Could Reshape Obesity Care
I just finished reading the full NEJM article on Retatrutide , the new triple-agonist weight-loss medication in development by Eli Lilly, and it’s one of the most compelling studies I’ve seen in a while. To be clear—this drug isn’t approved yet, but what the data shows is significant. If you’ve been following the incretin class of medications like I have (Zepbound, Wegovy, Mounjaro), this one raises the bar. Here’s the science in plain terms: 🧬 What is Retatrutide? It’s a once-weekly injectable that targets three receptors : GLP-1 (reduces appetite, improves glucose control) GIP (enhances insulin, may impact fat metabolism) Glucagon receptor (triggers fat burning by increasing energy output) Zepbound only hits GLP-1 and GIP. Adding the glucagon receptor into the mix is what makes Retatrutide so interesting—this third pathway could be why the results are so much more dramatic. 📊 Study Overview: 338 adults with obesity or overw...